The debate supports carrying forward TREM2 enhancement as a way to restore protective microglial response and reduce downstream tau spread only if a proximal endpoint changes before the late outcome. The decisive validation path is: stage-stratified TREM2 gain-of-function perturbation with microglial lipid handling, plaque compaction, and tau propagation endpoints.
No AI visual card yet
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
2 citations0 with PMIDValidation: 0%1 supporting / 1 opposing
✓For(1)
No supporting evidence
No opposing evidence
(1)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
TREM2 activation can be stage-dependent and may wo…
Opposing
MECH
AD-MASTER-PLAN-…
-
-
-
-
-
Legacy Card View — expandable citation cards
✓ Supporting Evidence
1
Preregistered claim: TREM2 enhancement reduces microglial dysfunction and downstream tau pathology, slowing AD…▼
Preregistered claim: TREM2 enhancement reduces microglial dysfunction and downstream tau pathology, slowing AD progression
AD-MASTER-PLAN-TREM2-20260428030753
✗ Opposing Evidence
1
TREM2 activation can be stage-dependent and may worsen inflammatory injury outside the right disease window
AD-MASTER-PLAN-TREM2-20260428030753
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-28 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Theorist position for analysis AD-MASTER-PLAN-TREM2-20260428030753: AD Master Plan preregistration: TREM2
Context: Preregistered claim: TREM2 enhancement reduces microglial dysfunction and downstream tau pathology, slowing AD progression
Primary claim: TREM2 enhancement as a way to restore protective microglial response and reduce downstream tau spread is a debate-worthy mechanism or quality claim, not just a restatement of the analysis title. The strongest version predicts a proximal readout that changes before a late outcome. For this AD master-plan preregistration, the debate should prese
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Skeptic critique for analysis AD-MASTER-PLAN-TREM2-20260428030753: AD Master Plan preregistration: TREM2
The analysis question is substantive, but the current record does not by itself prove the claim. The main dissent is: TREM2 activation can be stage-dependent and may worsen inflammatory injury outside the right disease window.
The debate should reject overclaiming in three forms. First, association or benchmark performance should not be treated as causality without a design that separates cause from consequence. Second, a positive average effect can hide subgroup failure across TREM2, AD,
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Domain expert assessment for analysis AD-MASTER-PLAN-TREM2-20260428030753: AD Master Plan preregistration: TREM2
The practical path is staged. Stage 1 should lock the data inputs, covariates, and endpoints. Stage 2 should run the most direct validation: stage-stratified TREM2 gain-of-function perturbation with microglial lipid handling, plaque compaction, and tau propagation endpoints. Stage 3 should connect the result to a reusable SciDEX artifact: a promoted hypothesis, a benchmark row with confidence intervals, a notebook reproducibility badge, or a revised preregistration.
Feasibility is
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{ "ranked_hypotheses": [ { "title": "TREM2 enhancement as a way to restore protective microglial response and reduce downstream tau spread requires proximal validation", "description": "The debate supports carrying forward TREM2 enhancement as a way to restore protective microglial response and reduce downstream tau spread only if a proximal endpoint changes before the late outcome. The decisive validation path is: stage-stratified TREM2 gain-of-function perturbation with microglial lipid handling, plaque compaction, and tau propagation endpoints.", "target_gene": "TREM
Price History
No price history recorded yet
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0000
Events (7d)
0
Clinical Trials (0)
No clinical trials data available
📚 Cited Papers (0)
No linked papers yet
📅 Citation Freshness Audit
Freshness score = exp(-age×ln2/5): halves every 5 years.
Green >0.6,
Amber 0.3–0.6,
Red <0.3.
No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.